search
Back to results

Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial

Primary Purpose

Vomiting in Infants and/or Children

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Ondansetron 4 MG
Sponsored by
Lizar Aguirre Pascasio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vomiting in Infants and/or Children

Eligibility Criteria

4 Years - 13 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presence of at least 2 vomits in the last 4 hours.
  • Negative tolerance test.
  • Signature of the informed consent by the parents or legal guardians.
  • Diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting.
  • Patients weighing 15 kg or more.

Exclusion Criteria:

  • Altered conciousness.
  • Sospected acute abdomen (appendicitis, invaginations...).
  • Suspicion or presence of obstructive disease.
  • Known severe digestive disease (Chron´s disease, ulcerative colitis...).
  • Suspected food poisoning.
  • Allergy to any of the drugs used in the study.
  • Severe dehydration.
  • Bilious vomiting.
  • Previous abdominal surgery.
  • Pathology that may affective degree of hydration of the patient (kidney failure, hypoalbuminemia..).
  • Admission requirement or intravenous rehydration for any reason.
  • Concomitant use of apomorphine.
  • In relation to the possible lengthening of the QT, patients with problems of previous arrhythmia should be excluded or that they are receiving concomitant medication that can lengthen the QT, that have electrolyte disturbances.
  • Patients receiving other serotonergic drugs.
  • Patients who have undergone a previous adenotonsillectomy.
  • Patients with hypocalcemia and/or hypomagnesemia.
  • Patients with hereditary fructose intolerance.
  • Diabetes patients.
  • Lactose intolerant patients.
  • Patients with indication of the low sodium diets.
  • Hypersensitivity to ondansetron or other antagonists of the 5-HT3.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Ondransetron

    Habitual Clinical Practice

    Arm Description

    Administration of ondansetron

    Habitual Clinical Practice

    Outcomes

    Primary Outcome Measures

    Percentage of children who return to medical/pediatric consultation for de same episode
    Is calculated percentage of children who return to medical/pediatric consultation for de same episode of vomiting

    Secondary Outcome Measures

    Full Information

    First Posted
    March 20, 2020
    Last Updated
    April 20, 2021
    Sponsor
    Lizar Aguirre Pascasio
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04318847
    Brief Title
    Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
    Official Title
    Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 10, 2021 (Anticipated)
    Primary Completion Date
    April 10, 2023 (Anticipated)
    Study Completion Date
    April 10, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Lizar Aguirre Pascasio

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This clinical trial is intended to evaluate the efficacy and safety of the administration of ondansetron in children with mild-moderate dehydration. The target population will be children between 4 and 13 years old who present vomiting.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Vomiting in Infants and/or Children

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    220 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Ondransetron
    Arm Type
    Experimental
    Arm Description
    Administration of ondansetron
    Arm Title
    Habitual Clinical Practice
    Arm Type
    No Intervention
    Arm Description
    Habitual Clinical Practice
    Intervention Type
    Drug
    Intervention Name(s)
    Ondansetron 4 MG
    Intervention Description
    Administration of ondansetron 4 mg or 8 mg according to weight
    Primary Outcome Measure Information:
    Title
    Percentage of children who return to medical/pediatric consultation for de same episode
    Description
    Is calculated percentage of children who return to medical/pediatric consultation for de same episode of vomiting
    Time Frame
    An average of 24 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    4 Years
    Maximum Age & Unit of Time
    13 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Presence of at least 2 vomits in the last 4 hours. Negative tolerance test. Signature of the informed consent by the parents or legal guardians. Diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting. Patients weighing 15 kg or more. Exclusion Criteria: Altered conciousness. Sospected acute abdomen (appendicitis, invaginations...). Suspicion or presence of obstructive disease. Known severe digestive disease (Chron´s disease, ulcerative colitis...). Suspected food poisoning. Allergy to any of the drugs used in the study. Severe dehydration. Bilious vomiting. Previous abdominal surgery. Pathology that may affective degree of hydration of the patient (kidney failure, hypoalbuminemia..). Admission requirement or intravenous rehydration for any reason. Concomitant use of apomorphine. In relation to the possible lengthening of the QT, patients with problems of previous arrhythmia should be excluded or that they are receiving concomitant medication that can lengthen the QT, that have electrolyte disturbances. Patients receiving other serotonergic drugs. Patients who have undergone a previous adenotonsillectomy. Patients with hypocalcemia and/or hypomagnesemia. Patients with hereditary fructose intolerance. Diabetes patients. Lactose intolerant patients. Patients with indication of the low sodium diets. Hypersensitivity to ondansetron or other antagonists of the 5-HT3.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Lizar Aguirre Pascasio, Dr
    Phone
    945007374
    Email
    LIZAR.AGUIRREPASCASIO@osakidetza.eus

    12. IPD Sharing Statement

    Learn more about this trial

    Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial

    We'll reach out to this number within 24 hrs